Avalo Therapeutics (Nasdaq: AVTX) announced completion of enrollment in its Phase 2 LOTUS trial of AVTX-009 for adults with hidradenitis suppurativa (HS).The trial exceeded its target of 222 patients with approximately 250 patients enrolled. LOTUS is a randomized, double-blind, placebo-controlled Phase 2 study (1:1:1) testing two AVTX-009 dose regimens versus placebo during a 16-week treatment phase. The primary endpoint is the proportion achieving HiSCR75 at Week 16. Secondary measures include HiSCR50/90, IHS4, draining fistula count, AN count, and PGA Skin Pain reductions. Topline data are expected in mid-2026. Trial identifiers: NCT06603077 and www.lotustrial.com.

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.

Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech company focused on IL-1β-based treatments, reported Q2 2025 financial results and business updates. The company's Phase 2 LOTUS trial for hidradenitis suppurativa (HS) has enrolled over 75% of planned patients, with topline data expected mid-2026.Financial highlights include $113.3 million in cash and short-term investments as of June 30, 2025, providing runway into 2028. Q2 2025 showed a net loss of $20.8 million ($1.92 per share), compared to net income of $98.5 million in Q2 2024. R&D expenses increased by $9.5 million to $14.1 million, primarily due to LOTUS trial costs.The company strengthened its leadership by appointing Rita Jain, M.D. to the Board of Directors, bringing valuable experience in clinical development and regulatory strategy.

YouTube video by The German Marshall Fund of the United States

Avalo Therapeutics (NASDAQ: AVTX) reported its Q1 2025 financial results and business updates. The company ended Q1 with $125 million in cash, providing runway into 2027 with potential extension into 2028. The Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa (HS) is progressing as planned, with topline data expected in 2026.Q1 2025 financial highlights include: net loss of $13.1 million ($1.25 per share), R&D expenses of $9.1 million (up $7.0M YoY), and G&A expenses of $5.5 million (up $2.4M YoY). The company is carefully evaluating the timing of additional development activities beyond LOTUS trial due to current market conditions. [ "Strong cash position of $125M providing runway into 2027, with potential extension to 2028", "Phase 2 LOTUS trial enrollment progressing on schedule with topline data expected in 2026", "Significant reduction in net loss to $13.1M in Q1 2025 from $121.3M in Q1 2024" ]

Bij Avantium hakt de aankondiging van alweer de vijfde emissie in slechts vier jaar er flink in. Vooral de omvang hiervan is zorgelijk.

Avalo strengthens financial position with $185M placement, extending runway to 2027. Phase 2 LOTUS trial in hidradenitis suppurativa progresses with new strategic leadership.

YouTube video by Lube Musical

YouTube video by neocloak

YouTube video by neocloak

Yianis Varoufakis told red. media “those who try very hard to extract a condemnation of the attack by Hamas” from him or his movement DiEM25 will “never get ...

Yianis Varoufakis told red. media “those who try very hard to extract a condemnation of the attack by Hamas” from him or his movement DiEM25 will “never get ...